Padmini Nathan
Optometrist · Frederick, MDNPI 1861550592
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.5%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 97.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2020 at $84,177 and has fallen 99.3% since, to $573 in 2025. Among optometrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $1122.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$194K
- Bausch & Lomb Americas Inc.$871
- Alcon$650
- Bausch & Lomb, A Division Of Bausch Health US, LLC$414
- Tarsus Pharmaceuticals, Inc.$351
- Johnson & Johnson Vision Care, Inc.$342
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1420%
- Food & beverage$4,2872%
- Gifts$170%
- Entertainment$140%
- Ownership interest$83,90542%
- Other$110,31456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $194,219 |
| Bausch & Lomb Americas Inc. | 25 | $871 |
| Alcon | 26 | $650 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $414 |
| Tarsus Pharmaceuticals, Inc. | 12 | $351 |
| Johnson & Johnson Vision Care, Inc. | 20 | $342 |
| Oyster Point Pharma, Inc. | 12 | $314 |
| Novartis | 14 | $238 |
| Coopervision Inc. | 12 | $237 |
| Sun Pharmaceutical Industries Inc. | 11 | $205 |
| AbbVie(2 entities) | 9 | $203 |
| Shire North American Group Inc | 2 | $149 |
| Amgen | 2 | $110 |
| ABB Con-cise Optical Group LLC | 2 | $91 |
| Kala Pharmaceuticals, Inc. | 3 | $56 |
| Oasis Medical, Inc. | 3 | $49 |
| Maculogix, Inc. | 1 | $41 |
| Dompe US, Inc. | 1 | $32 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Optos, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$194,219
- INFUSE$245
- DAILIES$142
- XIIDRA$125
- TRYPTYR$115
How this compares
$198,679 in reported general payments places this provider in the 95th percentile of 790 optometrist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 81 | $127,159 |
| XiidraLifitegrast | 13 | $24,084 |
| XdemvyLotilaner | 12 | $23,320 |
| TyrvayaVarenicline Tartrate | 14 | $14,826 |
| VyzultaLatanoprostene Bunod | 27 | $14,713 |
| Cyclosporine | 24 | $11,952 |
| MieboPerfluorohexyloctane/Pf | 15 | $10,856 |
| LumiganBimatoprost | 15 | $7,907 |
| Travoprost | 12 | $2,588 |
| Latanoprost | 40 | $385 |
| Timolol Maleate | 15 | $303 |
| ErythromycinErythromycin Base | 18 | $212 |
| Azelastine Hcl | 13 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $203 | $135,06696 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $871 | $49,65355 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $351 | $23,32012 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $314 | $14,82614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 optometrist providers in Maryland.
Other optometrist in Frederick
- Anupreet ChawlaFrederick$4K
- Nita GalaFrederick$4K
- Susan LathropFulton$337K
- Timothy EarleyOakland$276K
- Alan GlazierRockville$87K
- Andrew MorgensternBethesda$62K
- Devin SasserSilver Spring$40K
- Rizwana IqbalEllicott City$34K
- Brian WoolfPasadena$19K
- Vickie FangGaithersburg$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.